Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171834
Status:
COMPLETED
Last Update Posted:
2014-02-05
First Post:
2005-09-13
Brief Title:
Dose Escalating Study of the Safety and Efficacy of Patupilone q3w in Patients With Non-small Cell Lung Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open Label Phase III Dose Escalating Study Evaluating the Safety and Efficacy of EPO906 qw3 in Patients With Non-small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study objective is to evaluate the maximum tolerated dose safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None